Total Payments
$3,699
2024 Payments
$14.62
Companies
20
Transactions
92
Medicare Patients
2,517
Medicare Billing
$562,715
Payment Breakdown by Category
Food & Beverage$3,623 (97.9%)
Education$76.00 (2.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,623 | 90 | 97.9% |
| Education | $76.00 | 2 | 2.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| UCB, Inc. | $834.30 | 21 | $0 (2019) |
| Amgen Inc. | $600.70 | 6 | $0 (2020) |
| Biogen, Inc. | $418.09 | 6 | $0 (2019) |
| Lilly USA, LLC | $333.40 | 3 | $0 (2022) |
| Genentech USA, Inc. | $314.33 | 9 | $0 (2018) |
| ACADIA Pharmaceuticals Inc | $257.55 | 13 | $0 (2018) |
| Allergan, Inc. | $191.17 | 2 | $0 (2020) |
| ABBVIE INC. | $160.10 | 3 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $136.31 | 2 | $0 (2019) |
| Sunovion Pharmaceuticals Inc. | $117.09 | 6 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $14.62 | 1 | ABBVIE INC. ($14.62) |
| 2023 | $177.24 | 4 | AbbVie Inc. ($145.48) |
| 2022 | $235.61 | 2 | Lilly USA, LLC ($235.61) |
| 2020 | $241.98 | 2 | Allergan, Inc. ($125.44) |
| 2019 | $545.62 | 8 | Amgen Inc. ($225.35) |
| 2018 | $1,489 | 43 | UCB, Inc. ($367.29) |
| 2017 | $994.11 | 32 | UCB, Inc. ($441.99) |
All Payment Transactions
92 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/22/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $14.62 | General |
| Category: NEUROSCIENCE | ||||||
| 10/05/2023 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $21.79 | General |
| Category: NEUROSCIENCE | ||||||
| 08/02/2023 | Corium, LLC | Adlarity (Drug) | Food and Beverage | In-kind items and services | $15.15 | General |
| Category: Treatment of dementia of the Alzheimers type | ||||||
| 07/19/2023 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $16.61 | General |
| Category: PSYCHIATRY | ||||||
| 01/25/2023 | AbbVie Inc. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $123.69 | General |
| Category: NEUROSCIENCE | ||||||
| 06/22/2022 | Lilly USA, LLC | EMGALITY (Drug), REYVOW | Food and Beverage | Cash or cash equivalent | $117.93 | General |
| Category: Neuroscience | ||||||
| 06/22/2022 | Lilly USA, LLC | EMGALITY (Drug), REYVOW | Food and Beverage | In-kind items and services | $117.68 | General |
| Category: Neuroscience | ||||||
| 02/18/2020 | Amgen Inc. | Aimovig (Biological) | Food and Beverage | In-kind items and services | $116.54 | General |
| Category: Neuroscience | ||||||
| 01/23/2020 | Allergan, Inc. | UBRELVY (Drug) | Food and Beverage | Cash or cash equivalent | $125.44 | General |
| Category: NEUROSCIENCE | ||||||
| 12/04/2019 | Biogen, Inc. | Vumerity (Drug) | Food and Beverage | Cash or cash equivalent | $139.31 | General |
| Category: NEUROLOGY | ||||||
| 08/27/2019 | Amgen Inc. | Aimovig (Biological) | Food and Beverage | In-kind items and services | $113.71 | General |
| Category: Neuroscience | ||||||
| 06/25/2019 | Amgen Inc. | Aimovig (Biological) | Food and Beverage | In-kind items and services | $111.64 | General |
| Category: Neuroscience | ||||||
| 05/17/2019 | Supernus Pharmaceuticals, Inc. | TROKENDI XR (Drug) | Food and Beverage | Cash or cash equivalent | $14.19 | General |
| Category: AED | ||||||
| 02/23/2019 | Supernus Pharmaceuticals, Inc. | TROKENDI XR (Drug) | Food and Beverage | Cash or cash equivalent | $13.14 | General |
| Category: AED | ||||||
| 02/09/2019 | Teva Pharmaceuticals USA, Inc. | AJOVY (Drug) | Food and Beverage | In-kind items and services | $117.22 | General |
| Category: Central Nervous System | ||||||
| 01/25/2019 | Amneal Pharmaceuticals LLC | RYTARY (Drug) | Food and Beverage | In-kind items and services | $11.39 | General |
| Category: NEUROLOGY | ||||||
| 01/22/2019 | UCB, Inc. | Briviact (Drug) | Food and Beverage | In-kind items and services | $25.02 | General |
| Category: Neurology | ||||||
| 12/14/2018 | Sunovion Pharmaceuticals Inc. | APTIOM (Drug) | Food and Beverage | In-kind items and services | $20.05 | General |
| Category: CNS | ||||||
| 12/04/2018 | UCB, Inc. | Briviact (Drug) | Food and Beverage | In-kind items and services | $10.80 | General |
| Category: Neurology | ||||||
| 11/17/2018 | Teva Pharmaceuticals USA, Inc. | AJOVY (Drug) | Food and Beverage | In-kind items and services | $19.09 | General |
| Category: Central Nervous System | ||||||
| 11/15/2018 | UCB, Inc. | Briviact (Drug) | Food and Beverage | In-kind items and services | $106.55 | General |
| Category: Neurology | ||||||
| 11/10/2018 | Avanir Pharmaceuticals, Inc. | NUEDEXTA (Drug), ONZETRA Xsail | Food and Beverage | In-kind items and services | $18.48 | General |
| Category: pseudobulbar affect (PBA) | ||||||
| 10/29/2018 | UCB, Inc. | Vimpat (Drug) | Food and Beverage | In-kind items and services | $4.14 | General |
| Category: Neurology | ||||||
| 10/27/2018 | US WorldMeds, LLC | MYOBLOC (Biological), APOKYN, Xadago | Food and Beverage | In-kind items and services | $21.04 | General |
| Category: Neurology | ||||||
| 10/24/2018 | Lilly USA, LLC | — | Food and Beverage | In-kind items and services | $97.79 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 398 | 517 | $156,423 | $61,017 |
| 2022 | 13 | 630 | 821 | $427,699 | $141,992 |
| 2021 | 12 | 671 | 862 | $523,241 | $164,450 |
| 2020 | 13 | 818 | 1,092 | $541,465 | $195,256 |
Total Patients
2,517
Total Services
3,292
Medicare Billing
$562,715
Procedure Codes
45
All Medicare Procedures & Services
45 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 136 | 213 | $53,250 | $17,476 | 32.8% |
| 95957 | Measurement of brain wave activity (eeg), digital analysis | Office | 2023 | 42 | 53 | $26,553 | $11,634 | 43.8% |
| 95819 | Measurement of brain wave activity (eeg), awake and asleep | Office | 2023 | 32 | 32 | $22,400 | $11,176 | 49.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 62 | 87 | $22,620 | $9,382 | 41.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 59 | 59 | $20,650 | $9,201 | 44.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 24 | 28 | $4,200 | $1,698 | 40.4% |
| 93040 | Electrocardiogram (ecg) 1 to 3 leads with review by physician | Office | 2023 | 43 | 45 | $6,750 | $450.33 | 6.7% |
| 95715 | Measurement of brain wave activity with video (veeg), 12-26 hours with intermittent monitoring | Office | 2022 | 16 | 47 | $160,000 | $38,465 | 24.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 163 | 277 | $69,250 | $25,431 | 36.7% |
| 95819 | Measurement of brain wave activity (eeg), awake and asleep | Office | 2022 | 52 | 52 | $36,400 | $18,541 | 50.9% |
| 95957 | Measurement of brain wave activity (eeg), digital analysis | Office | 2022 | 62 | 73 | $36,573 | $15,654 | 42.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 78 | 105 | $27,300 | $13,787 | 50.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 76 | 76 | $26,600 | $11,522 | 43.3% |
| 95724 | Measurement of brain wave activity with video (veeg), 61-84 hours with review and report by health care professional | Office | 2022 | 17 | 17 | $23,630 | $4,405 | 18.6% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Office | 2022 | 13 | 13 | $7,696 | $4,097 | 53.2% |
| 95700 | Measurement of brain wave activity (eeg), continuous | Office | 2022 | 17 | 17 | $15,300 | $3,478 | 22.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 42 | 50 | $7,500 | $3,199 | 42.6% |
| 93268 | Electrocardiogram (ecg) up to 30 days continuous with symptom monitoring and review and report by health care professional | Office | 2022 | 17 | 17 | $6,800 | $2,568 | 37.8% |
| 93040 | Electrocardiogram (ecg) 1 to 3 leads with review by physician | Office | 2022 | 62 | 62 | $9,300 | $620.33 | 6.7% |
| 93227 | Electrocardiogram (ecg) 2-day continuous with review by health care professional | Office | 2022 | 15 | 15 | $1,350 | $224.85 | 16.7% |
| 95715 | Measurement of brain wave activity with video (veeg), 12-26 hours, with intermittent monitoring and maintenance | Office | 2021 | 24 | 70 | $236,600 | $56,594 | 23.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 187 | 302 | $75,500 | $28,989 | 38.4% |
| 95819 | Measurement and recording of brain wave (eeg) activity, awake and asleep | Office | 2021 | 52 | 52 | $36,400 | $19,272 | 52.9% |
| 95957 | Digital analysis of electrical brain wave activity (eeg) | Office | 2021 | 69 | 81 | $40,581 | $16,706 | 41.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 85 | 85 | $29,450 | $13,987 | 47.5% |
About Dr. David Chen, M.D
Dr. David Chen, M.D is a Neurology healthcare provider based in Dallas, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/22/2005. The National Provider Identifier (NPI) number assigned to this provider is 1609868918.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Chen, M.D has received a total of $3,699 in payments from pharmaceutical and medical device companies, with $14.62 received in 2024. These payments were reported across 92 transactions from 20 companies. The most common payment nature is "Food and Beverage" ($3,623).
As a Medicare-enrolled provider, Chen has provided services to 2,517 Medicare beneficiaries, totaling 3,292 services with total Medicare billing of $562,715. Data is available for 4 years (2020–2023), covering 45 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Dallas, TX
- Active Since 08/22/2005
- Last Updated 04/17/2025
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1609868918
Products in Payments
- Briviact (Drug) $662.49
- Aimovig (Biological) $489.24
- OCREVUS (Biological) $314.33
- NUPLAZID (Drug) $257.55
- EMGALITY (Drug) $235.61
- UBRELVY (Drug) $161.85
- TECFIDERA (Drug) $143.22
- Vimpat (Drug) $140.14
- Vumerity (Drug) $139.31
- AJOVY (Drug) $136.31
- QULIPTA (Drug) $123.69
- APTIOM (Drug) $117.09
- Rebif (Biological) $99.57
- NAMENDA XR (Drug) $65.73
- TROKENDI XR (Drug) $49.35
- NUEDEXTA (Drug) $49.18
- Neupro (Drug) $31.67
- MYOBLOC (Biological) $21.04
- REXULTI (Drug) $16.61
- ONFI (Drug) $16.36
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Dallas
Nirav Pavasia, M.d, M.D
Neurology — Payments: $1.3M
Neurology $1.3M
Benjamin Greenberg, Md, MD
Neurology — Payments: $691,893
Neurology $691,893
Steven Herzog, M.d, M.D
Neurology — Payments: $519,302
Neurology $519,302
Waleed El-Feky, M.d, M.D
Neurology — Payments: $469,716
Neurology $469,716
Mark Alberts, Md, MD
Neurology — Payments: $417,917
Neurology $417,917
Adnan Subei, D.o, D.O
Neurology — Payments: $274,043
Neurology $274,043